|
|
Blood, Vol. 109, Issue 6, 2579-2588, March 15, 2007
Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress
Blood Isham et al.
109: 2579
Supplemental materials for: Isham et al, Vol 109, Issue 6, 2579-2588
Files in this Data Supplement:
- Figure S1. Effects of chaetocin on dexamethasone- or doxorubicin-resistant myeloma cell lines (PDF, 24.4 KB) -
Effects of chaetocin (A) or dexamethasone (B) on paired MM1S/R dexamethasone-sensitive/-resistant myeloma cells are shown in the top panels, indicating no cross-resistance of MM1R cells to chaetocin. Effects of chaetocin (A) or doxorubicin (B) on paired doxorubicin-sensitive/-resistant RPMI 8226/8226 D40 myeloma cells are shown in the bottom panels, indicating only modest cross-resistance of 8226 D40 cells to chaetocin. Shown results are representative of duplicate experiments. In panels C and D, exposures to drugs were of 24-hour durations, with survival assessed at that time; trypan-blue exclusion was used to assess surviving cell numbers in all experiments.
- Figure S2. Effects of dexamethasone or doxorubicin on patient myeloma cells and paired normal leukocytes (PDF, 23.2 KB) -
Results from 3 representative myeloma patients (of 20 similarly assessed) are displayed, corresponding to the patients displayed in Figure 3A-C. Survival was assessed using trypan-blue exclusion after 24-hour drug exposures ex vivo, as described for Figure 3 and in the text.
|
|
